0001567619-19-000484.txt : 20190104 0001567619-19-000484.hdr.sgml : 20190104 20190104151727 ACCESSION NUMBER: 0001567619-19-000484 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20190104 DATE AS OF CHANGE: 20190104 EFFECTIVENESS DATE: 20190104 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Cardiol Therapeutics Inc. CENTRAL INDEX KEY: 0001702123 IRS NUMBER: 000000000 STATE OF INCORPORATION: A6 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-329709 FILM NUMBER: 19509670 BUSINESS ADDRESS: STREET 1: 2275 UPPER MIDDLE ROAD EAST, STE. 101 CITY: OAKVILLE STATE: A6 ZIP: L6H 0C3 BUSINESS PHONE: 905-491-6793 MAIL ADDRESS: STREET 1: 2275 UPPER MIDDLE ROAD EAST, STE. 101 CITY: OAKVILLE STATE: A6 ZIP: L6H 0C3 D 1 primary_doc.xml X0708 D LIVE 0001702123 Cardiol Therapeutics Inc. 2275 UPPER MIDDLE ROAD EAST, STE. 101 OAKVILLE A6 ONTARIO, CANADA L6H 0C3 (905) 491-6793 ONTARIO, CANADA None None Corporation true 2017 David Elsley 2275 Upper Middle Road East, Ste. 101 Oakville A6 ONTARIO, CANADA L6H 0C3 Executive Officer Director Promoter Eldon R. Smith 2275 Upper Middle Road East, Ste. 101 Oakville A6 ONTARIO, CANADA L6H 0C3 Executive Officer Director Promoter Chris Waddick 2275 Upper Middle Road East, Ste. 101 Oakville A6 ONTARIO, CANADA L6H 0C3 Executive Officer Anthony E. Bolton 2275 Upper Middle Road East, Ste. 101 Oakville A6 ONTARIO, CANADA L6H 0C3 Executive Officer Promoter Guillermo Torre-Amione 2275 Upper Middle Road East, Ste. 101 Oakville A6 ONTARIO, CANADA L6H 0C3 Director Deborah Brown 2275 Upper Middle Road East, Ste. 101 Oakville A6 ONTARIO, CANADA L6H 0C3 Director Peter Pekos 2275 Upper Middle Road East, Ste. 101 Oakville A6 ONTARIO, CANADA L6H 0C3 Director Terry Lynch 2275 Upper Middle Road East, Ste. 101 Oakville A6 ONTARIO, CANADA L6H 0C3 Director Iain Chalmers 2275 Upper Middle Road East, Ste. 101 Oakville A6 ONTARIO, CANADA L6H 0C3 Director Biotechnology Decline to Disclose 06b false 2018-12-20 true true true true true Units of Class A common shares and Class A common share purchase warrants; each warrant exercisable at C$6.50 for 2 years, subject to acceleration by Issuer under specified conditions false 0 AltaCorp Capital Inc. None AltaCorp Capital (USA) Inc. 155053 4800 Montgomery Lane, Suite 450 Bethesda MD MARYLAND 20814 CO COLORADO FL FLORIDA GA GEORGIA IL ILLINOIS NJ NEW JERSEY TX TEXAS false Haywood Securities (USA) Inc. 42072 None None 200 Burrard Street, Suite 700 Vancouver A1 BRITISH COLUMBIA, CANADA V6C 3L6 DE DELAWARE OH OHIO false Mackie Research Capital Corporation None AltaCorp Capital (USA) Inc. 155053 199 Bay Street, Suite 4500 Toronto A6 ONTARIO, CANADA M5L 1G2 true Raymond James Ltd. None AltaCorp Capital (USA) Inc. 155053 40 King Street W., Suite 5300 Toronto A6 ONTARIO, CANADA M5H 3Y2 true Echelon Wealth Partners Inc. None AltaCorp Capital (USA) Inc. 155053 1 Adelaide Street, Suite 2100 Toronto A6 ONTARIO, CANADA M5C 2V9 true Paradigm Capital Inc. None AltaCorp Capital (USA) Inc. 155053 95 Wellington Street W., Suite 2101 Toronto A6 ONTARIO, CANADA M5J 2N7 true 8423198 3662260 4760938 (c) represents potential warrant exercise price by U.S. investors; Cdn$1.3495=US$1.00 false 9 219736 0 In addition to cash commission, the agents received 59,307 broker warrants exercisable at C$5.00 for 12 months 0 false Cardiol Therapeutics Inc. /s/ Chris Waddick Chris Waddick Chief Financial Officer 2019-01-04